Oramed Pharmaceuticals (OTC:ORMP.OB) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an oral insulin capsule currently in Phase 2 trials, the Company is seeking to revolutionize the treatment of diabetes.
Frost and Sullivan Award Oramed

August 25, 2009

Frost and Sullivan Honors Oramed Pharmaceuticals with the 2009 European Oral Drug Delivery Technology Innovation Award

... read more »

Press Release
January 19, 2010

Oramed Pharmaceuticals Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801

... read more »  
Press Center | Terms & Conditions | Privacy Statement Design and programming by BIGDESIGN Creative Agency | All rights reserved © 2009 Oramed